Aldeyra Therapeutics (ALDX) Retained Earnings (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Retained Earnings came in at -$487.4 million in Q1 2026, down 5.95% YoY from -$518.2 million in Q1 2025, and down 0.71% on a QoQ basis from -$484.0 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Retained Earnings (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Retained Earnings data on file, last reported at -$487.4 million in Q1 2026.
- Quarterly Retained Earnings fell 5.95% year-over-year to -$487.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$487.4 million (down 5.95% YoY) and the FY2025 annual result came in at -$484.0 million, down 7.52% from the prior year.
- Retained Earnings eased to -$487.4 million in Q1 2026, from -$484.0 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $66540.0 in Q3 2024 to a low of -$487.4 million in Q1 2026.
- A 5-year average of -$284.1 million and a median of -$395.8 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings surged 100.0% — and 2025, when it tumbled 15187753.85%.
- Tracing ALDX's Retained Earnings over 5 years: stood at -$356.7 million in 2022, then retreated by 4.38% to -$372.3 million in 2023, then declined by 20.89% to -$450.1 million in 2024, then decreased by 7.52% to -$484.0 million in 2025, then fell by 0.71% to -$487.4 million in 2026.
- The last three Retained Earnings figures came in at -$487.4 million (Q1 2026), -$484.0 million (Q4 2025), and -$477.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - | 4.38 Bn |
| 10 | Aldeyra Therapeutics | 92.89 Mn | 92.89 Mn | - | -492.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -492.86 Mn |
| Mar 31, 2026 | -487.41 Mn |
| Dec 31, 2025 | -483.96 Mn |
| Sep 30, 2025 | -477.50 Mn |
| Jun 30, 2025 | -469.81 Mn |
| Mar 31, 2025 | -460.04 Mn |
| Dec 31, 2024 | -450.11 Mn |
| Sep 30, 2024 | 66,540.00 |
| Jun 30, 2024 | -419.19 Mn |
| Mar 31, 2024 | -3,029.00 |
| Mar 31, 2023 | -372.33 Mn |
| Dec 31, 2022 | -356.72 Mn |
| Sep 30, 2022 | -285,733.00 |
| Jun 30, 2022 | -285,763.00 |
| Mar 31, 2022 | -61,677.00 |
| Dec 31, 2021 | -294.69 Mn |
| Sep 30, 2021 | -278.94 Mn |
| Jun 30, 2021 | -263.14 Mn |
| Mar 31, 2021 | -248.21 Mn |
| Dec 31, 2020 | -236.92 Mn |